Live Online Training: Setting Specifications AND Stability Testing
Im Auftrag der ECA Academy

Live Online Training: Setting Specifications AND Stability Testing Im Auftrag der ECA Academy

Seminar Nr. 18470

All times mentioned are CET.

Kosten

ECA-Member: EUR 1380,--
Non ECA Member: EUR 1780,--
EU/GMP Inspectorates: EUR 890,--
APIC Member Discount: EUR 1580,--

Alle Preise zzgl. MwSt.

Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail: info@concept-heidelberg.de

Sprecher

Dr Ulli Backofen, Boehringer Ingelheim Pharma, Germany
Dr Thomas Fürst, Boehringer Ingelheim Pharma, Germany
Dr Cornelia Nopitsch-Mai, Quality Assessor, Germany
Dr Thomas Uhlich, Bayer, Germany
Dr Wolfgang Grimm, Germany
Dr Jordi Ruiz-Combalia, Audit GMP, Spain

Zielsetzung

Setting Specifications and Acceptance Criteria:
This Live Online Training covers different aspects of specifications for Active Pharmaceutical Ingredients (APIs = Drug Substances), biological substances and pharmaceutical drug products from an analytical and regulatory perspective. The examples presented will help the participants to define or to evaluate specifications in their daily work.
 
Stability Testing for Drug Substances and Drug Products:
This Live Online Training is intended to provide information on different aspects of stability testing.
 
The event will be opened by an overview of stability testing with a special focus on important changes in current revisions of ICH Guidelines. In the subsequent presentations, practical aspects of stability testing for drug substances and throughout drug development are discussed. Furthermore, stability testing for drug products and a risk based approach for stability testing covering different climatic zones are presented. In addition, the specific challenges of data evaluation will be addressed.

Hintergrund

Setting Specifications and Acceptance Criteria:
In the development of new pharmaceutical products it is a great challenge to establish meaningful and reasonable specifications, which are scientifically sound and appropriate for APIs (chemical and biological drug substances), excipients and drug products. According to ICH Guideline Q6A, a specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described.

The analytical result, which will be compared to the specification, is affected by the variability of the measurement itself and depends also on the sampling process and on the variability of the manufacturing process of the tested product itself. This makes statistical considerations essential and consideration of the associated measurement uncertainties vital when setting or complying with specifications.

Analytical methods that were not “stability-indicating” are frequently cited in FDA 483s and Warning Letters. This Live Online Training will thus address how to set impurity limits for related substances and degradation products based on method capability and stability results.
 
Stability Testing for Drug Substances and Drug Products:
Analytical methods that were not “stability-indicating” are frequently cited in FDA 483s and Warning Letters. This Live Online Training will thus address how to set impurity limits for related substances and degradation products based on method capability and stability results.
 
The analytical result, which will be compared to the specification, is affected by the variability of the measurement itself and depends also on the sampling process and on the variability of the manufacturing process of the tested product itself. This makes statistical considerations essential and consideration of the associated measurement uncertainties vital when setting or complying with specifications.

Zielgruppe

This Live Online Training is of particular interest to specialists from QA, QC and Regulatory Affairs departments of the API and pharmaceutical industry and CROs as well as to members of the EU inspectorates and authorities.

During the Q&A sessions, participants have the opportunity to exchange their experiences they gained with the different aspects of ‘specifications’ with the experts from the API and pharmaceutical industry as well as with members of competent authorities.

Technical Requirements

For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At https://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Programm

Setting Specifications and Acceptance Criteria on 02 December 2020:
 
09.00 – 09.15 h
Introduction

09.15 – 09.45 h
Basic Principles for Setting of Release and Shelf-life Specifications
  • Some basic statistics: Distribution and Variation
  • Variation and specifications
  • Changes over time and shelf life specification
  • Process Capability
  • Control strategy
  • QbD or not to be
09.45 – 10.45 h
Current Regulatory Requirements for Setting Specifications (ICH Q6A)
  • Regulatory overview
  • Impact of pharmacopoeial provisions
  • Setting specifications for active substances and finished products
  • Justification of specifications
  • Changes/variations
  • Introduction to the requirements of risk assessment with focus on setting specifications for heavy metals
  • How authorities will proceed in respect of submitting the required documentation for approved marketed products
10.45 – 11.00 h
Break

11.00 – 11.45 h
Specifications of Biopharmaceuticals
  • Overview of regulatory requirements
  • Critical Quality attributes and Control Strategy
  • Differences between NCEs and NBEs
  • Considerations for Drug Substance and Drug Product
  • Specifications during early and late stage development
  • Acceptance criteria at release and for shelf life
11.45 – 12.30 h and 13.15 – 13.45 h
Rational Development and Justification of API Specifications (Part 1 and Part 2)
  • Impurity identification and profiling
  • Impurity tracking
  • Classification of impurities
  • Thresholds for Drug Substance
  • Assay, organic impurities and degradation products, water, residual solvents, heavy metals, particle size distribution, polymorphs, genotoxic impurities etc.
12.30 – 13.15 h
Break

Q&A sessions after each presentation ensure interaction and that your questions are answered.

13.45 – 14.45 h
Setting Specifications throughout Drug Development
  • Specifications throughout development
  • Specifications in Pharmacopoeias
  • Stability of the manufacturing process
  • Specifications for comparator products
14.45 – 15.00 h
Break

15.00 – 15.45 h and 16.00 – 16.30 h
Rational Development and Justification of Drug Product Specifications (Part 1 and Part 2)
  • Specification types
  • Regulatory limits and limits based on data
  • Typical tests for different types of drug products, e.g.assay, purity, content uniformity, dissolution, fill volume, endotoxines, sterility etc.
15.45 – 16.00 h
Break

16.30 – 17.15 h
Specifications for Specific Drug Products – What is the Difference to Standard Formulations
  • Specific aspects required for special drug products, e.g.
  • Gastro-intestinal therapeutic systems (GITS) or osmotic-controlled release oral delivery systems (OROS)
  • Transdermal patches
  • Orally inhaled and nasal drug products (OINDPs)
 
Stability Testing for Drug Substances and Drug Products on 03 December 2020:
 
09.00 – 09.15 h
Introduction
 
09.15 – 10.45 h
Current ICH and CHMP Guidelines for Stability Testing
  • Overview of Stability Guidelines
  • Concepts of Stability testing
  • Retest period and Shelf-life
  • Post-marketing Stability Studies
  • Future Activities
10.45 – 11.00 h
Break

11.00 – 12.00 h
Stability Testing throughout Drug Development
  • Must the development stability programme meet ICH Q1A?
  • Stability testing from early development to product launch
  • Clinical stability for comparators
  • Site specific stability
12.00 – 13.00 h
Break

13.00 – 14.00 h
Stability Testing for Drug Substances
  • Stability protocols
  • Stress testing
  • Photostability testing
  • Documentation
14.00 – 14.15 h
Break

14.15 – 15.15 h
Stability Testing for Drug Products
  • Strategy of Stability Testing
  • Performance of new Drug Products
  • Related Finished Products with existing substances
  • Follow-up Stability Testing
15.15 – 15.30 h
Break

15.30 – 16.30 h
Evaluation of Stability Results – Statistical Considerations
  • Sample number and replication
  • Trend analysis
  • Outliers
  • Pooling of batch data
  • Shelf life prediction

Zurück

GMP Seminare nach Thema

Cookies helfen uns bei der Bereitstellung unserer Dienste. Durch die Nutzung unserer Dienste erklären Sie sich damit einverstanden, dass wir Cookies setzen. Weitere Informationen

OK